Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| HSBC Holdings | 1.73% | $17.05M | £222.90B | 45.63% | 80 Outperform | |
| GlaxoSmithKline | 1.46% | $14.34M | £91.50B | 53.84% | 77 Outperform | |
| Novartis AG | 1.41% | $13.89M | CHF242.43B | 30.85% | 80 Outperform | |
| Murata Manufacturing Co | 1.20% | $11.84M | ¥6.66T | 33.00% | 77 Outperform | |
| Standard Chartered | 1.14% | $11.20M | £40.75B | 61.38% | 77 Outperform | |
| ING GROEP | 1.11% | $10.95M | €70.29B | 49.98% | 61 Neutral | |
| Roche Holding AG | 1.04% | $10.27M | CHF294.84B | 47.36% | 73 Outperform | |
| Barclays | 1.04% | $10.24M | £67.02B | 56.82% | 78 Outperform | |
| ArcelorMittal | 1.03% | $10.13M | €41.61B | 104.02% | 73 Outperform | |
| AstraZeneca | 1.02% | $10.03M | £240.98B | 31.92% | 80 Outperform |